Day 21 Slit2-knockdown tumors had fewer F4/80+ myeloid cells than day 18 Slit2-overexpressing tumors or day 21 controls, according to immunofluorescence examination of tumor sections. This evidence concerns the gene SLIT2 and neoplasm.